HOME > Publications

Publications

2023

Publication (International Journal)
  1. Morino E, Mine S, Tomita N, Uemura Y, Shimizu Y, Saito S, Suzuki T, Okumura N, Iwasaki H, Terada J, Ainai A, Sakai Y, Park　E, Seki S, Akazawa S, Shimojima M, Shiwa-Sudo N, Virhuez-Mendoza M, Miyauchi K, Moriyama S, Iwata-Yoshikawa N, Harada M, Harada S, Hishiki T, Kotaki R, Matsumura T, Miyamoto S, Kanno T, Isogawa M, Watashi K, Nagata N, Ebihara H, Takahashi Y, Maeda K, Matano T, Wakita T, Suzuki T, Sugiura W, Ohmagari N, Ujiie M.
    Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults.
    NEJM Evid.3(3):EVIDoa2300290,2024.
  2. Ujiie M, Nakamoto T, Iwamoto N, Tsuzuki S.
    Large-scale resurgence of herpangina in Japan, following the easing of COVID-19 measures.
    IJID Reg. 10:15-17,2023.
  3. Iwasaki H, Salmon S, Matsuzawa Y, Lee S, Takagi K, Nomoto H, Ishikane M, Ujiie M, Ohmagari N.
    Global Outbreak Alert and Response Network (GOARN) focal point engagement meeting with partners in Japan.
    Western Pac Surveill Response J. 15(5 Spec edition):1-3, 2024.
  4. Terada-Hirashima J, Takamatsu Y,Shimizu Y, Uemura Y, Takeuchi S J, Tomita N, Matsuda K, Maeda K, Yamamoto S, Fukunaga A, Ohmagari N, Mikami A, Sonoda K, Ujiie M, Mistuya H,Sugiura W.
    Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
    Hum Vaccin Immunother. 19(1):2193074,2023.
  5. Wilson E, Goswami J,Baqui H A, Doreski A P, Perez-Marc G, Zaman K, Monroy J, Duncan J A C, Ujiie M, Rämet M.
    Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
    N Engl Med. 389(24):2233-2244,2023.
  6. Inoue Y, Li Y, Yamamoto S, Fukunaga A, Ishiwari H, Ishii M, Miyo K, Ujiie M, Sugiura W, Ohmagari N.
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine 41(49): 7317-7321,2023.
  7. Okumura N, Ishikane M, Ujiie M, Ohmagari N.
    "Take" after LC16m8 for mpox.
    Int J Infect Dis, 134:290-291,2023.
  8. Yano R, Terada-Hirashima J, Uemura Y, Tomita N, Shimizu Y, Iwasaki H, Okumura N, Suzuki T, Saito S, Ujiie M.
    Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study.
    JMIR research protoc, 12: e46955,2023.
  9. Tomita N, Terada-Hirashima J, Uemura Y, Shimizu Y, Iwasaki H, Yano R, Suzuki T, Saito S, Okumura N, Sugiura W, Ohmagari N, Ujiie M.
    An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox.
    Hum vaccin immunother,19(2):2242219,2023.
  10. Matsuoka O, Ujiie M, Kikuchi H, Otake S, Chansinghakul D, Inoue T, Varghese K, Sirisuphmitr N, Hashiguchi T, Zambrano B.
    Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
    Jpn J Infec Dis,76(3):174-182,2023.
  11. Miyazato Y, Terada M, Ujiie M, Saito S, Moriya A, Ando M, Ohmagari N.
    A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan.
    J Travel Med,30(2)taac070,2023.
  12. Hayakawa K, Binh NG, Co DX, Thach PT, Phuong Thuy PT, Chau NQ, Huong ML, Van Thanh D, Phuong DM, Miyoshi-Akiyama T, Nagashima M, Ohmagari N.
    Clinical and microbiological evaluation of ventilator-associated pneumonia in an intensive care unit in Vietnam.
    Infect Prev Pract. 5(4):100318,2023.
  13. Kamegai K, Hayakawa K, Yamamoto K, Nomoto H, Komaki-Yasuda K, Kano S, Ohmagari N.
    Imported severe Plasmodium falciparum infection in the first trimester of pregnancy complicated by post-artemisinin delayed hemolysis and intrauterine fetal death, a case report.
    Trop Med Health. 51(1):25,2023.
  14. Okumura N, Hayakawa K, Yamamoto K, Yamada G, Mezaki K, Ohmagari N.
    Effectiveness of oral cephalexin in antibiotic-course completion for methicillin-susceptible Staphylococcus aureus-induced bacteremic vertebral osteomyelitis.
    BMC Infect Dis. 23(1):307,2023.
  15. Suzuki M, Hayakawa K, Asai Y, Terada M, Kitajima K, Tsuzuki S, Moriya A, Moriya K, Uchiyama-Nakamura F, Ohmagari N.
    Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test.
    J Infect Chemother. 29(5):539-545,2023.
  16. Maeki T, Tajima S, Ando N, Wakimoto Y, Hayakawa K, Kutsuna S, Kato F, Taniguchi S, Nakayama E, Lim CK, Saijo M.
    Analysis of cross-reactivity among flaviviruses using sera of patients with dengue showed the importance of neutralization tests with paired serum samples for the correct interpretations of serological test results for dengue.
    J Infect Chemother. 29(5):469-474,2023.
  17. Suzuki T, Saito S, Tsuzuki S, Ashida S, Takakusaki M, Yoshikawa T, Shimojima M, Ebihara H, Ohmagari N, Morioka S,
    Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox.
    BMJ Open. 13(8): e069550,2023.
  18. Kamo-Imai A, Togano T, Sato M, Kawakami Y, Inaba K, Shimazu H, Igarashi S, Tanaka K, Terada M, Kinoshita-Iwamoto N, Saito S, Kutsuna S, Hangaishi A, Morioka S, Takahashi K, Miyata S, Ohmagari N,
    The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan.
    Transfusion and Apheresis Science.62(3):103687,2023.
  19. Morioka S, Ohmagari N, Kurosu H, Kutsuna S, Sato M, Kunimitsu T, Koshiba M,
    Building an effective infection prevention and control system in Japan: a historical review. World Health Organization.
    https://www.who.int/publications/i/item/9789290620051.
  20. Kubo T, Hayakawa K, Akiyama Y, Morioka S, Ohmagari N,
    A case of confirmed pre-symptomatic transmission of mpox.
    J Infect Chemother 29(10):1008-1009,2023.
  21. Kato M, Yoshimatsu F, Yamamoto T, Kobayashi N, Kikuchi T, Matsuoka S, Matano T, Iwahashi K, Ikushima Y, Shiono S, Ishikane M, Morioka S, Nakamoto T, Yoshimi I, Saito T,
    Development of a partnership between academia, community, and government in response to the 2022 mpox outbreak in Japan.
    Nihon Koshu Eisei Zasshi. 71(2):103-107,2024.
  22. Suzuki T, Asai Y, Takahashi K, Sanada M, Shimanishi Y, Terada M, Sato L, Inada M, Yamada G, Akiyama Y, Oshiro Y, Shiratori K, Togano T, Takamatsu Y, Kenji M, Matsunaga A, Ishizaka Y, Nomoto H, Iwamoto N, Saito S, Kutsuna S, Morioka S, Ohmagari N,
    Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved.
    Heliyon. 9(10):e20568,2023.
  23. Akiyama Y, Morioka S, Tsuzuki S, Yoshikawa T, Yamato M, Nakamura H, Shimojima M, Takakusaki M, Saito S, Takahashi K, Sanada M, Komatsubara M, Takebuchi K, Yamaguchi E, Suzuki T, Shimokawa K, Kurosu T, Kawahara M, Oishi K, Ebihara H, Ohmagari N,
    Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
    J Infect Chemother. 30(6):488-493,2024.
  24. Saito S, Kutsuna S, Akifumi I, Hase R, Oda R, Terada J, Shimizu Y, Uemura Y, Takamatsu Y, Yasuhara A, Shiratori K, Satake M, Sakamoto N, Miyazaki Y, Shimizu H, Togano T, Matsunaga A, Okuma K, Hamaguchi I, Fujisawa K, Nagashima M, Ashida S, Terada M, Kimura A, Morioka S, Matsubayashi K, Tsuno NH, Kojima M, Kuramitsu M, Tezuka K, Ikebe E, Ishizaka Y, Kenji M, Hangaishi A, Mikami A, Sugiura W, Ohmagari N, Mitsuya H.
    Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label.randomized, controlled trial.
    J Infect Chemother. 29(9):869-874,2023.
  25. Miyazato Y, Tsuzuki S, Matsunaga A, Morioka S, Terada M, Saito S, Iwamoto N, Kutsuna S, Ishizaka Y, Ohmagari N,
    Association between SARS-CoV-2 anti-spike antibody titers and the development of post-COVID conditions: A retrospective observational study.J Infect Chemother. 29(9):869-874,2023
  26. Suzuki T, Morioka S, Yamamoto K, Saito S, Iida S, Teruya K, Takasaki J, Hojo M, Hayakawa K, Kutsuna S, Miyamoto S, Ozono S, Suzuki T, Kodama EN, Ohmagari N.
    Nasopharyngeal SARS-CoV-2 may not be dispersed by a high-flow nasal cannula.
    Sci Rep. 13(1):2669,2023.
  27. Morioka S, Tsuzuki S, Maruki T, Terada M, Miyazato Y, Kutsuna S, Saito S, Shimanishi Y, Takahashi K, Sanada M, Ashida S, Akashi M, Kuge C, Osanai Y, Tanaka K, Suzuki M, Hayakawa K, Ohmagari N.
    Epidemiology of hai conditions beyond 1 year: a cross-sectional study.
    Public Health. 216:39-44,2023.
  28. Inada M, Saito S, Tsuzuki S, Okumura N, Sato L, Kamegai K, Sanada M, Komatsubara M, Shimojima M, Ebihara H, Kasuya F, Nagashima M, Sadamasu K, Yamamoto K, Ujiie M, Morioka S, Ohmagari N.
    Treatment with tecovirimat of the first two cases of monkeypox in Japan.
    J Infect Chemother. 29(4):418-21,2023.
  29. Yamamoto K, Asai Y, Nakagawa H, Nakatani I, Hayashi K, Matono T, Kanai S, Yamato M, Mikawa T, Shimatani M, Shimono N, Shinohara K, Kitaura T, Nagasaka A, Manabe A, Komiya N, Imakita N, Yamamoto Y, Iwamoto N, Okumura N, Ohmagari N.
    Characteristics of preventive intervention acceptance for international travel among clients aged 60 years and older from a Japanese multicenter pretravel consultation registry.
    J Infect Chemother. 29(12):1137-1144,2023.
  30. Maruki T, Yamamoto K, Yamato M, Sahara T, Shirano M, Sakamoto N, Hase R, Shinohara K, Yoshimura Y, Imakita N, Kodama F, Yamamoto Y, Yokota K, Yoshimi Y, Hasegawa C, Kutsuna S, Ohmagari N.
    Epidemiological trends of traveler's diarrhea in Japan: An analysis of imported infectious disease registry data from 2017-2022.
    Glob Health Med. 5(6):372-376,2023.
  31. Yamamoto K.
    Furuncular Myiasis in a Returnee from Sub-Saharan Africa.
    Intern Med. 63(1):141-142,2024.
  32. Okumura N, Yamada G, Yamamoto K, Tsuzuki S.
    Methodological Issues in a Retrospective Study on Short-course Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections in China.
    Clin Infect Dis. ciae146,2024.
  33. Sato L, Iwamoto N, Kakumoto Y, Tsuzuki S, Togano T, Ishikane M, Okumura N, Yamada G, Inada M, Suzuki T, Hojo M, Takasaki J, Sasaki R, Kimura A, Teruya K, Okamoto T, Hayakawa K, Hara H, Iseki K, Ohmagari N.
    Unfractionated Heparin Safety in COVID-19: Incidence and Risks of Bleeding Complications in Japan.
    J Atheroscler Thromb.Epub jat.64448,2024.
  34. Iwamoto N, Takamatsu Y, Asai Y, Tsuchiya K, Matsuda K, Oshiro Y, Inamura N, Terada M, Nemoto T, Kimura M, Saito S, Morioka S, Kenji M, Mitsuya H, Ohmagari N.
    High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with in vitro viral neutralizing activity.
    Heliyon. 10(2):e24513,2024.
  35. Maruki T, Nomoto H, Iwamoto N, Yamamoto K, Kurokawa M, Iwatsuki-Horimoto K, Yamayoshi S, Suzuki Y, Kawaoka Y, Ohmagari N.
    Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
    J Infect Chemother. S1341-321X(24)00012-6,2024.
  36. Kamegai K, Iwamoto N, Ishikane M, Yamamoto K, Horii K, Kubota S, Hangaishi A, Shimazu H, Togano T, Yamashita H, Yamada Y, Ohmagari N.
    A novel protocol for de-isolating moderately and severely immunocompromised COVID-19 patients.
    Glob Health Med. 5(6):366-371,2023.
  37. Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y.
    Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
    Cell Rep. 42(12):113580,2023.
  38. Akiyama Y, Iwamoto N, Kamada K, Yoshida A, Osugi A, Mitarai S, Suzuki T, Yamamoto K, Nagashima M, Horai T, Ohmagari N.
    Aortic endograft infection by Mycobacterium abscessus subsp. massiliense with acquired clarithromycin resistance: a case report.
    BMC Infect Dis . 23(1):694,2023.
  39. Ishiwada N, Shinjoh M, Kusama Y, Arakawa H, Ohishi T, Saitoh A, Suzuki A, Tsutsumi H, Nishi J, Hoshino T, Mitsuda T, Miyairi I, Iwamoto-Kinoshita N, Kobayashi H, Satoh K, Shimizu A, Takeshita K, Tanaka T, Tamura D, Tokunaga O, Tomita K, Nagasawa K, Funaki T, Furuichi M, Miyata I, Yaginuma M, Yamaguchi Y, Yamamoto S, Uehara S, Kurosaki T, Okada K, Ouchi K.
    Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan 2022.
    Pediatr Infect Dis J. 42(10):e369-e376,2023.
  40. Kimura A, Takagi T, Thamamongood T, Sakamoto S, Ito T, Seki I, Okamoto M, Aono H, Serada S, Naka T, Imataka H, Miyake K, Ueda T, Miyanokoshi M, Wakasugi K, Iwamoto N, Ohmagari N, Iguchi T, Nitta T, Takayanagi H, Yamashita H, Kaneko H, Tsuchiya H, Fujio K, Handa H, Suzuki H.
    Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4.
    Ann Rheum Dis. 82(9):1153-1161,2023.
  41. Itoh N, Akazawa N, Kurai H, Kawamura I, Okinaka K, Fujita T, Sekiya N, Takeda K, Shiotsuka M, Ishikane M, Iwamoto N, Ohmagari N, Suzuki T.
    A nationwide cross-sectional study using a web-based questionnaire survey of the duration of isolation of COVID-19 inpatients with cancer at Japanese cancer centers.
    J Infect Chemother. 29(12):1185-1188,2023.
  42. Shoji K, Asai Y, Akiyama T, Tsuzuki S, Matsunaga N, Suzuki S, Iwamoto N, Funaki T, Miyairi I, Ohmagari N.
    Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis.
    J Infect Chemother. 29(9):930-933,2023.
  43. Miyamoto S*, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, Ozono S, Aihara K, Takahashi K, Tsuchihashi Y, Ishikane M, Arashiro T, Saito S, Ainai A, Hirata Y, Iida S, Katano H, Tobiume M, Tokunaga K, Fujimoto T, Suzuki M, Nagashima M, Nakagawa H, Narita M, Kato Y, Igari H, Fujita K, Kato T, Hiyama K, Shindou K, Adachi T, Fukushima K, Nakamura-Uchiyama F, Hase R, Yoshimura Y, Yamato M, Nozaki Y, Ohmagari N, Suzuki M, Saito T, Iwami S, Suzuki T.
    Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 120(52):e2314808120,2023.
  44. Goto R, Muraki Y*, Inose R, Ichii M, Sawada K, Mizuno K, Koizumi R, Tsuzuki S, Ishikane M, Ohmagari N.
    Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database.
    J Pharm Health Care Sci. 9(1):35,2023.
  45. Muraki Y*, Koizumi R, Kusama Y, Inose R, Ishikane M, Ohmagari N.
    Necessity for a System Implementing Therapeutic Drug Monitoring in Outpatient Settings Based on the Actual Use of Voriconazole Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan: A Descriptive Epidemiological Study.
    Biol Pharm Bull. 46(10):1490-1493,2023.
  46. Ishii N*, Shiratori Y, Ishikane M, Omata F.
    Population effectiveness of endoscopy screening for mortality reduction in gastric cancer.
    DEN Open. 4(1):e296,2023.
  47. Shinjoh M*, Furuichi M, Tsuzuki S, Iqbal A, Fukushima N, Soen S, Fukushima H, Kobayashi K, Yamada G, Narabayashi A, Tsunematsu K, Maeda N, Shimoyamada M, Yoshida M, Kuramochi Y, Shibata A, Yamaguchi Y, Yaginuma M, Takahashi T, Ishikane M, Sugaya N; Keio Pediatric Influenza Research Group.
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 41(33):4777-4781,2023.
  48. Ide S*, Ishikane M, Aoyagi K, Ono A, Asai Y, Tsuzuki S, Kusama Y, Gu Y, Kodama E, Ohmagari N.
    Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013-2018.
    PLoS One. 18(6):e0287297,2023.
  49. Kawashima A, Nomoto H, Takagi H, Hayakawa K, Komaki-Yasuda K, Kano S, Ohmagari N.
    Mansonella perstans infection in a Gabonese immigrant in Japan: an illustrative case of a clinical conundrum and management dilemma.
    J Travel Med. 30(7):taad126,2023.
  50. Nomoto H, Yamamoto K, Kutsuna S, et al.
    Evaluation of potential rabies exposure among Japanese international travelers: A retrospective descriptive study.
    PLoS One. 18(8):e0287838,2023.
  51. Moriyama Y, Takaya S, Nishijima T, Sobel HL, Ohmagari N.
    Maintaining health-system functionality in response to the surge of COVID-19 cases due to the Omicron variant, Japan.
    Western Pacific Surveillance and Response. 14(5):6–6,2023.
  52. Moriyama Y, Doi A, Shinkai N, Nasu S, Mesaki K, Horii K, et al.
    Clinical characteristics and risk factors for multidrug-resistant bacterial isolation in patients with international travel history.
    Am J Infect Control. 51(6):660–7,2023.
  53. Akiyma Y*, Saito S, Tsuzuki S, Mezaki K, Ohmagari N.
    Pyelonephritis due to Escherichia coli in the older population in Japan: Impacts on activities of daily living and medical costs.
    Glob Health Med. 6(1):77-82,2024.
  54. Nakamura K*, Hayakawa K, Tsuzuki S, Ohmagari N.
    Bloodstream infections in the elderly Japanese population: Current reality and countermeasures.
    Glob Health Med. 6(1):90-92,2024.
  55. Morioka S*, Nikaido M, Tsuzuki S, Kutsuna S, Saito S, Hayakawa K, Sugiyama M, Ohmagari N.
    Epidemiology of post-COVID conditions beyond 3 years and factors associated with their persistence longer than 2 years: A cross-sectional study.
    J Infect Chemother. S1341-321X(24)00044-8,2024.
  56. Ogawa T*, Tsuzuki S, Ohbe H, Matsui H, Fushimi K, Yasunaga H, Kutsuna S.
    Analysis of Differences in Characteristics of High-Risk Endemic Areas for Contracting Japanese Spotted Fever, Tsutsugamushi Disease, and Severe Fever With Thrombocytopenia Syndrome.
    Open Forum Infect Dis. 11(2):ofae025,2024.
  57. Suzuki T*, Asai Y, Tsuzuki S, Nomoto H, Matsunaga N, Kodama N E, Hayakawa K, Ohmagari N.
    Real-world effectiveness of full and booster mRNA vaccination for coronavirus disease 2019 against disease severity during the delta- and omicron-dominant phases: A propensity score-matched cohort study using the nationwide registry data in Japan.
    J Microbiol Immunol Infect. 57(1):20-29,2024.
  58. Kitano T, Tsuzuki S*, Koizumi R, Aoyagi K, Asai Y, Kusama Y, Ohmagari N.
    Factors Associated with Geographical Variability of Antimicrobial Use in Japan.
    Infect Dis Ther. 12(12):2745-2755,2023.
  59. Ishioka H*, Fujii N, Tajima T, Suzuki S, Tsuzuki S, Matsunaga N, Ohmagari N.
    Cumulative antibiogram preparation among hospitals participating in the Japan Surveillance for Infection Prevention and Healthcare Epidemiology.
    J Infect Chemother. 2023 Nov 7:S1341-321X(23)00274-X. doi: 10.1016/j.jiac.2023.11.002.
  60. Tsuzuki S*, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H.
    Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-16 to 2020-21 seasons: from the VENUS study.
    J Antimicrob Chemother. 78(12):2976-2982,2023.
  61. Hayakawa K*, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, Shinohara K, Hashimoto T, Hase R, Matono T, Kato H, Mawatari M, Hara H, Hamada Y, Saito S, Ohmagari N, Doi Y.
    Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Antimicrob Agents Chemother. 67(10):e0051023,2023.
  62. Asai Y*, Ohashi T, Imai K, Murata K, Tsuzuki S, Matsunaga N, Ohmagari N.
    Differences in COVID-19 treatment across Japan: Analysis of the COVID-19 Registry Japan (COVIREGI-JP).
    J Infect Chemother. S1341-321X(23)00210-6,2023
  63. Otake S*, Kusama Y, Tsuzuki S, Myojin S, Kimura M, Kamiyoshi N, Takumi Toru, Ishida A, Kasai M.
    Comparing the effects of antimicrobial stewardship at primary emergency centers.
    Pediatrics International. 65(1):e15614,2023.
  64. Tsuzuki S*.
    The future of COVID-19 surveillance in Japan.
    Lancet Infect Dis. S1473-3099(23)00292,2023.
  65. Nakamura K*, Hayakawa K, Tsuzuki S, Ide S, Nomoto H, Nakamoto T, Yamada G, Yamamoto K, Ohmagari N.
    Clinical outcomes and epidemiological characteristics of bacteremia in the older Japanese population.
    J Infect Chemother. S1341-321X(23)00158-7,2023.
  66. Tsuzuki S*.
    Beutels P. The estimated disease burden of COVID-19 in Japan from 2020 to 2021.
    J Infect Public Health. 16(8):1236-1243,2023.
Presentations at International Conferences and Forums
  1. Iwamoto N.
    Antimicrobial stewardship and Trend in oral antibiotic use in Japanese children.
    The 18th Congress of ASPR (ASPR 2023), online,11,2023.
  2. Kamegai K, Iwamoto N, Itoh N, Ishikane M, Asai Y, Akazawa N, Fuwa N, Takasaki J, Hojo M, Hangaishi A, Togano T, Teruya K, Takahashi K, Hirata Y, Kanno T, Katano H, Miyamoto S, Saito T, Suzuki T, Ohmagari N.
    Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant among Immunocompromised Patients.
    IDweek2023, Boston,USA,10,2023.
  3. Makoto Inada ,Noriko Iwamoto, Hidetoshi Nomoto et al.
    Characteristics of Streptococcal Toxic Shock Syndrome Caused by Different Beta-Hemolytic Streptococci Species: A Single-Center Retrospective Study.
    IDweek2023, Boston,USA,10,2023.
  4. Ishikane M.
    The infectivity of SARS-CoV-2 in immunocompromised patients and their de-isolation.
    USJCMSP 2024 EID Pacific Rim Conference, ARI Panel Meeting. Incheon, Korea,3, 2024
  5. Kato M*, Yoshimatsu F, Yamamoto T, Kobayashi N, Kikuchi T, Matsuoka S, Matano T, Iwahashi K, Ikushima Y, Shiono S, Ishikane M, Morioka S, Nakamoto T, Yoshimi I, Saito T.
    Building an Academia-Community-Government Partnership in the early phase in Japan to respond to the 2022 mpox outbreak.
    NCHCMM,Atlanta, Georgia ,July, 2023
  6. Ishikane M*, Unoki-Kubota H, Moriya A, Ando H, Kaburagi Y, Katsuno T, Terada-Hirashima J, Hikida S, Iwamoto N, Kimura M, Ohmagar N.
    Evaluation of a rapid direct polymerase chain reaction method for the detection of severe acute respiratory syndrome coronavirus 2.
    The 33th ECCMID. Copenhagen, Denmark,4, 2023
  7. Tsuzuki S*, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H.
    The association between seasonal influenza vaccination and antimicrobial consumption in Japan from 2014/15 to 2019/20 season: from VENUS study database
    ECCMID2023, Copenhagen, Denmark. 4, 2023
  8. Tsuzuki S*, Asai Y, Ibuka Y, Nakaya T, Ohmagari N, Hens N.Beutels P.
    Social contact patterns in Japan in the COVID-19 pandemic during and after the Tokyo Olympic Games.
    ECCMID2023, Copenhagen, Denmark.4, 2023
  9. Koizumi R*, Tsuzuki S, Aoyagi K, Fujitomo Y, Asai Y, Ohmagari N..
    Study of factors contributing to the decrease in antimicrobial consumption since the COVID-19 pandemic in Japan.
    ECCMID2023, Copenhagen, Denmark.4, 2023

Fiscal Year

SITE MAP ＋